Navigation Links
DURECT Provides Update on CHRONOGESIC(R) Research Program
Date:4/7/2008

CUPERTINO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals has stated that it intends to return the rights to CHRONOGESIC(R) licensed from DURECT Corporation for the U.S. and Canada. CHRONOGESIC is a product candidate consisting of a sufentanil containing implantable device intended for the treatment of moderate-to-severe chronic pain. As a result, the Development, Commercialization and Supply License Agreement between Endo and DURECT entered into in November 2002 will terminate. This return of CHRONOGESIC rights has no effect on DURECT and Endo's collaboration with respect to the sufentanil transdermal patch (TRANSDUR(TM)-Sufentanil) licensed by Endo from DURECT for the U.S. and Canada.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies focused on treating chronic and episodic diseases and conditions. The Company currently has multiple late-stage pharmaceutical products in development initially focused on significant unmet medical needs in pain management, with a number of research programs underway in a variety of other therapeutic areas. For more information, please visit http://www.durect.com.

NOTE: CHRONOGESIC(R) and TRANSDUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. TRANSDUR-Sufentanil is a drug candidate under development and has not been submitted or approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statement in this press release regarding DURECT's emergence as a specialty pharmaceutical company and DURECT's product candidates are forward- looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's (and that of its third party collaborators where applicable) abilities to obtain approvals from regulatory agencies with respect to its development activities and product candidates, design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the product candidates, consummate collaborative agreements relating to our product candidates and technologies, manufacture and commercialize the product candidates, obtain marketplace acceptance of the product candidates and manage and obtain capital to fund its growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K dated March 13, 2008 under the heading "Risk Factors."


'/>"/>
SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT to Participate in Cowen Annual Healthcare Conference
2. DURECT to Participate in Susquehanna Financial Healthcare Conference
3. DURECT to Present at BIO CEO Investor Conference 2008
4. DURECT to Present at 2007 BIO Investor Forum
5. DURECT to Present at UBS Global Life Sciences Conference
6. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
7. LIFE Provides Medical Books and Surgical Supplies to Iraq
8. Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand
9. Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating
10. Flagship Global Health Provides 2008 Financial Guidance
11. MedPage Today(R) Provides First-Time Live Video Coverage of Medical Meeting Press Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... The National Campaign to Prevent ... Access to Contraception for Women Servicemembers and Dependents Act of 2017. The bill, ... help to ensure that all members of the Armed Forces receive high quality ...
(Date:4/28/2017)... ... 28, 2017 , ... Somnoware, a leading provider of digital ... enables sleep physicians to create and edit their interpretation reports. This solution greatly ... familiar interface that does not require additional training to use. It also allows ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – it also ... hours without sleep can compromise motor reaction time, which can increase the risk of having ... sharing the following tips from the NSF to help you sleep better and feel better:, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces the ... instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ... hour rated lamps utilize the existing electronic ballast, saving labor and maintenance costs. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and ... more adverse experiences than children in the general population. That’s because foster care ... or other family challenges. While no fault of their own, youth who have ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... AMSTERDAM , April 20, 2017  AbbVie ... that 99 percent (n=145/146) of chronic hepatitis C ... 4, 5 or 6 and compensated cirrhosis (Child-Pugh ... post-treatment (SVR 12 ) with its investigational, pan-genotypic ... rates were seen following 12 weeks of ...
Breaking Medicine Technology: